BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28870205)

  • 1. Maintenance of stemness is associated with the interation of LRP6 and heparin-binding protein CCN2 autocrined by hepatocellular carcinoma.
    Jia Q; Bu Y; Wang Z; Chen B; Zhang Q; Yu S; Liu Q
    J Exp Clin Cancer Res; 2017 Sep; 36(1):117. PubMed ID: 28870205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCN2-MAPK-Id-1 loop feedback amplification is involved in maintaining stemness in oxaliplatin-resistant hepatocellular carcinoma.
    Liao X; Bu Y; Jiang S; Chang F; Jia F; Xiao X; Song G; Zhang M; Ning P; Jia Q
    Hepatol Int; 2019 Jul; 13(4):440-453. PubMed ID: 31250351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulated HOXC8 Expression Is Associated with Poor Prognosis and Oxaliplatin Resistance in Hepatocellular Carcinoma.
    Xu P; Zhang X; Ni W; Fan H; Xu J; Chen Y; Zhu J; Gu X; Yang L; Ni R; Chen B; Shi W
    Dig Dis Sci; 2015 Nov; 60(11):3351-63. PubMed ID: 26123838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.
    Yin X; Tang B; Li JH; Wang Y; Zhang L; Xie XY; Zhang BH; Qiu SJ; Wu WZ; Ren ZG
    J Exp Clin Cancer Res; 2017 Nov; 36(1):166. PubMed ID: 29169374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GRP78 activates the Wnt/HOXB9 pathway to promote invasion and metastasis of hepatocellular carcinoma by chaperoning LRP6.
    Xiong H; Xiao H; Luo C; Chen L; Liu X; Hu Z; Zou S; Guan J; Yang D; Wang K
    Exp Cell Res; 2019 Oct; 383(1):111493. PubMed ID: 31310747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of the Wnt co-receptor LRP6 promotes hepatocarcinogenesis and enhances cell invasion.
    Tung EK; Wong BY; Yau TO; Ng IO
    PLoS One; 2012; 7(5):e36565. PubMed ID: 22570728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells.
    Yin X; Zheng SS; Zhang L; Xie XY; Wang Y; Zhang BH; Wu W; Qiu S; Ren ZG
    Gene; 2017 Jan; 596():53-88. PubMed ID: 27729273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remodeling of hepatic stellate cells orchestrated the stroma-derived oxaliplatin-resistance through CCN3 paracrine in hepatocellular carcinoma.
    Liao X; Bu Y; Chang F; Jia F; Song G; Xiao X; Zhang M; Ning P; Jia Q
    BMC Cancer; 2019 Dec; 19(1):1192. PubMed ID: 31805888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inositol hexaphosphate sensitizes hepatocellular carcinoma to oxaliplatin relating inhibition of CCN2-LRP6-β-catenin-ABCG1 signaling pathway.
    Liao X; Zhang Y; Xu B; Ali A; Liu X; Jia Q
    J Cancer; 2021; 12(20):6071-6080. PubMed ID: 34539880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-202 suppresses cell proliferation in human hepatocellular carcinoma by downregulating LRP6 post-transcriptionally.
    Zhang Y; Zheng D; Xiong Y; Xue C; Chen G; Yan B; Ye Q
    FEBS Lett; 2014 May; 588(10):1913-20. PubMed ID: 24704686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix stiffness-mediated effects on stemness characteristics occurring in HCC cells.
    You Y; Zheng Q; Dong Y; Xie X; Wang Y; Wu S; Zhang L; Wang Y; Xue T; Wang Z; Chen R; Wang Y; Cui J; Ren Z
    Oncotarget; 2016 May; 7(22):32221-31. PubMed ID: 27050147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Connective tissue growth factor is overexpressed in human hepatocellular carcinoma and promotes cell invasion and growth.
    Xiu M; Liu YH; Brigstock DR; He FH; Zhang RJ; Gao RP
    World J Gastroenterol; 2012 Dec; 18(47):7070-8. PubMed ID: 23323010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single nucleotide variant in microRNA-1269a promotes the occurrence and process of hepatocellular carcinoma by targeting to oncogenes SPATS2L and LRP6.
    Min P; Li W; Zeng D; Ma Y; Xu D; Zheng W; Tang F; Chen J; Shi J; Hu H; Wang J; Yang D; Liu J; Zhang J; Zhang M
    Bull Cancer; 2017 Apr; 104(4):311-320. PubMed ID: 28081866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition.
    Huan HB; Yang DP; Wen XD; Chen XJ; Zhang L; Wu LL; Bie P; Xia F
    J Exp Clin Cancer Res; 2017 Jun; 36(1):86. PubMed ID: 28646927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
    Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/β-catenin pathway.
    Lo RC; Leung CO; Chan KK; Ho DW; Wong CM; Lee TK; Ng IO
    Cell Death Differ; 2018 Aug; 25(8):1426-1441. PubMed ID: 29445127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance.
    Yang S; Wang XQ
    BMC Cancer; 2017 May; 17(1):344. PubMed ID: 28526069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
    Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
    Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.